Drug Profile
NVP 0902
Alternative Names: NVP-0902Latest Information Update: 03 Aug 2016
Price :
$50
*
At a glance
- Originator Navipharm
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis
Most Recent Events
- 30 Nov 2013 Launched for Osteoporosis in South Korea (unspecified route)
- 31 Dec 2012 Phase-III clinical trials in Osteoporosis in South Korea (unspecified route) prior to December 2012
- 31 Dec 2012 Preregistration for Osteoporosis in South Korea (unspecified route)